Ashley Gallagher, Associate Editor

The Apothecary Shoppe in Utah knows patients by name, garners new business via word of mouth.

The treatment from Keytruda and Merck shows a clinical response of 89% for individuals with unresectable metastatic desmoplastic melanoma.

Findings show that study participants experienced improvements in both blood sugar control and the lipid profile.

A new scientific statement from the American Heart Association notes that the process falls short for those who are not white.

The data support the use of interventions at home, including frequent handwashing, physical distancing, regular surface disinfection, and wearing a mask.

A linear mixed-effect model for repeated estimated glomerular filtration rate measurements at baseline and a follow-up visit, up to 5 years after baseline, shows results.

41% of patients report moderate-to-severe issues, with Black individuals 3 times more likely to develop these difficulties.

But analysis does suggest a small increase in risk for individuals who used cigarettes and electronic nicotine delivery systems together.

Limiting added or free sugar is recommended to reduce the adverse effects, especially in cardiometabolic disease.

Analysis indicates that there was a larger increase of filled prescriptions for individuals who delivered by cesarean birth.

These are used to help reduce inappropriate testing, where an expert consults with medical directors of infection prevention and control for a test-order override.

Individuals treated with the drugs from AstraZeneca demonstrate clinically meaningful and statistically significant improvement.

State-level respiratory syncytial virus hospitalization rates for 2022 could be the highest seen since 2006, analysis published in Frontiers in Pediatrics indicate.

Many long-term therapies rely solely on load amelioration, but new ones are needed, according to investigators.

Individuals who are rituximab-naïve remained stable after 2 years of follow-up, the analysis shows.

The patient had no significant past medical complications and was fully immunized for the age-based recommendation from the Advisory Council and Immunization Practices, study shows.

Women who are pregnant should continue or start treatment with alternative or preferred antiretroviral therapies for viral suppression, investigators suggest.

The disease is the continuation of new symptoms 3 months after the initial SARS-CoV-2 infection and at least lasting 2 months after infection, according to the health organization.

Study results show significant differences in pCR rates, but the differences were not subtype-specific.

Investigators analyze to see if there was an association of expected benefits and risk of vaccination.

Health benefits last for at least 5 years if shedding pounds occur via a lifestyle change program, the results of a research review show.

Additionally, study results show a clinically meaningful overall survival trend in the overall population among individuals with primary advanced or recurrent disease.

Investigators suggest that funding mechanisms and interpersonal support systems are unsustainable for long-term care.

This method has proven economically appealing, but further confirmation of these findings is needed, according to investigators.

Clinical trial findings show that olaparib, given in the neoadjuvant setting, was feasible with 100% of participants able to receive the planned 2 cycles.

Fomepizole, an FDA-approved drug to treat methanol poisoning, and erythromycin could offer a novel therapeutic option to fight drug-resistant S. pneumoniae.

Investigators suggest that sleep interventions may help to reduce the risk of self-harm in female adolescents with depression and anxiety.

The data underscore the need for biomarker testing to identify patients who may be eligible for this therapy, according to physician from Memorial Sloan Kettering Cancer Center.

Asian Americans often develop the disease at a normal weight, which would be overlooked by current screening guidelines, investigators say.

The drug from AstraZeneca and Ionis Pharmaceuticals demonstrates a sustained benefit through 66 weeks for those with hereditary transthyretin-mediated amyloid polyneuropathy.